Welcome to our dedicated page for Essa Pharma SEC filings (Ticker: EPIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page aggregates historical SEC filings for ESSA Pharma Inc. (former NASDAQ: EPIX), a British Columbia–incorporated pharmaceutical company that was previously focused on developing novel and proprietary therapies for patients with prostate cancer. These filings document ESSA’s regulatory history as a U.S.-reporting issuer and provide detailed information on the corporate steps that led to its acquisition by XenoTherapeutics Inc. and the delisting of its common shares.
Among the key documents available are multiple Forms 8-K reporting material events related to the Business Combination Agreement with XenoTherapeutics, the subsequent Amendment Agreement, and the consummation of the court-approved plan of arrangement under the Business Corporations Act (British Columbia). These filings describe the consideration received by ESSA shareholders, including cash payments and non-transferable contingent value rights (CVRs), as well as the company’s large return of capital distribution made as part of the discontinuance and winding-up of its business.
The filings also include a Form 25 (Form 25-NSE) filed by Nasdaq Stock Market LLC on October 9, 2025, which formally removes ESSA’s common stock from listing and registration on Nasdaq. Related 8-K disclosures explain ESSA’s request that Nasdaq suspend trading in its shares and the purchaser’s intention to file a Form 15 to terminate registration under Section 12(g) of the Exchange Act and suspend reporting obligations under Sections 13 and 15(d).
Using Stock Titan’s tools, readers can quickly locate ESSA’s quarterly and annual reports, current reports on Form 8-K, and transaction-related exhibits, while AI-powered summaries help interpret complex legal and financial language. This makes it easier to understand how the arrangement was structured, how shareholder votes and court approvals were obtained, and what the delisting and deregistration steps mean for the historical EPIX ticker and former ESSA securityholders.
ESSA Pharma (EPIX) reported interim results as of June 30, 2025 showing a strong cash position and a major strategic shift. The company held $85.95 million in cash and $23.67 million in short-term U.S. Treasury securities, giving working capital of $108.90 million and total assets of $110.50 million. ESSA recorded a net loss of $18.91 million for the nine months ended June 30, 2025 and an accumulated deficit of $226.91 million. In October 2024 ESSA terminated clinical trials of its lead candidate, masofaniten (EPI-7386), and withdrew related IND/CTA filings. Subsequent to the quarter, ESSA entered a Business Combination Agreement with XenoTherapeutics under which shareholders are currently estimated to receive approximately US$1.91 per share plus one non-transferable contingent value right (CVR) per share entitling holders to a pro rata portion of up to US$2.95 million (up to US$0.06 per CVR). The Transaction requires court and shareholder approvals and is expected to close in the second half of 2025.
ESSA Pharma (EPIX) is asking Securityholders to approve a court‑approved Plan of Arrangement to be voted on at a virtual Special Meeting on September 10, 2025. Under the Arrangement, Xeno Acquisition Corp. (a subsidiary of XenoTherapeutics) will acquire all outstanding common shares for an estimated Cash Amount of approximately US$1.91 per share (subject to reduction by a Distribution) plus one CVR per share entitling holders to a pro‑rata portion of up to US$2,950,000 less specified deductions related to litigation and costs.
The Board and an independent Transaction Committee unanimously recommend the Arrangement and received a fairness opinion from Leerink Partners dated July 13, 2025. The Company received court authorization for a concurrent capital reduction and a proposed aggregate Distribution of US$80,000,000 (scheduled on or about August 22, 2025). As of the Record Date (August 5, 2025) there were 44,338,550 common shares outstanding, 7,830,523 Options and 2,920,000 Warrants. Closing is expected on or about September 18, 2025, after required shareholder votes and court orders, and will result in delisting from Nasdaq and deregistration under the Exchange Act.
FAQ
What is the current stock price of Essa Pharma (EPIX)?
What is the market cap of Essa Pharma (EPIX)?
